Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Average Rating of “Hold” by Brokerages

Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) have earned an average rating of “Hold” from the twenty-eight brokerages that are presently covering the stock, Marketbeat.com reports. Six investment analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and nine have issued a buy rating on the company. The average 12-month target price among brokerages that have covered the stock in the last year is $33.84.

A number of equities research analysts have recently weighed in on SRPT shares. Royal Bank Of Canada raised their price target on shares of Sarepta Therapeutics from $16.00 to $18.00 and gave the company a “sector perform” rating in a research note on Thursday, January 8th. Wells Fargo & Company cut their target price on shares of Sarepta Therapeutics from $50.00 to $45.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 5th. Wedbush boosted their target price on shares of Sarepta Therapeutics from $32.00 to $34.00 and gave the stock an “outperform” rating in a research note on Friday, January 23rd. Robert W. Baird dropped their price target on Sarepta Therapeutics from $21.00 to $15.00 and set a “neutral” rating for the company in a research note on Tuesday, November 4th. Finally, Barclays assumed coverage on Sarepta Therapeutics in a report on Wednesday, January 28th. They set an “equal weight” rating and a $20.00 price objective on the stock.

Sarepta Therapeutics Stock Down 2.7%

Shares of SRPT opened at $19.73 on Thursday. The firm has a 50 day simple moving average of $21.59 and a two-hundred day simple moving average of $19.94. The company has a debt-to-equity ratio of 0.78, a current ratio of 2.95 and a quick ratio of 1.79. Sarepta Therapeutics has a one year low of $10.41 and a one year high of $120.05. The company has a market cap of $2.07 billion, a P/E ratio of -6.55, a P/E/G ratio of 0.51 and a beta of 0.39.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings results on Monday, November 3rd. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.02 by ($0.15). The business had revenue of $399.36 million during the quarter, compared to the consensus estimate of $331.51 million. Sarepta Therapeutics had a negative net margin of 11.25% and a negative return on equity of 4.85%. The company’s revenue for the quarter was down 14.5% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.62 EPS. Research analysts forecast that Sarepta Therapeutics will post 2.67 EPS for the current fiscal year.

Insider Activity at Sarepta Therapeutics

In other news, COO Ian Michael Estepan sold 13,187 shares of the business’s stock in a transaction dated Tuesday, December 16th. The stock was sold at an average price of $22.31, for a total transaction of $294,201.97. Following the sale, the chief operating officer directly owned 193,300 shares in the company, valued at approximately $4,312,523. The trade was a 6.39% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 7.60% of the company’s stock.

Institutional Investors Weigh In On Sarepta Therapeutics

Several hedge funds have recently added to or reduced their stakes in SRPT. Vanguard Group Inc. increased its position in Sarepta Therapeutics by 9.2% in the 4th quarter. Vanguard Group Inc. now owns 11,810,729 shares of the biotechnology company’s stock valued at $254,167,000 after acquiring an additional 993,283 shares during the period. Erste Asset Management GmbH increased its holdings in Sarepta Therapeutics by 65.7% in the third quarter. Erste Asset Management GmbH now owns 2,685,945 shares of the biotechnology company’s stock valued at $50,588,000 after purchasing an additional 1,064,530 shares during the period. Aberdeen Group plc raised its position in Sarepta Therapeutics by 13.6% during the 4th quarter. Aberdeen Group plc now owns 2,251,593 shares of the biotechnology company’s stock worth $48,454,000 after purchasing an additional 268,829 shares during the last quarter. First Trust Advisors LP raised its position in Sarepta Therapeutics by 209.1% during the 3rd quarter. First Trust Advisors LP now owns 1,939,781 shares of the biotechnology company’s stock worth $37,380,000 after purchasing an additional 1,312,220 shares during the last quarter. Finally, Geode Capital Management LLC lifted its holdings in Sarepta Therapeutics by 3.0% during the 2nd quarter. Geode Capital Management LLC now owns 1,875,997 shares of the biotechnology company’s stock worth $32,085,000 after buying an additional 55,076 shares during the period. 86.68% of the stock is currently owned by institutional investors and hedge funds.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.